Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hidden kidney disease: study tracks missed diagnoses in millions with high blood pressure

NCT ID NCT06372431

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study looks at how often chronic kidney disease (CKD) is diagnosed in adults with high blood pressure who have early signs of kidney trouble but no prior CKD diagnosis. Researchers will review medical records and follow patients over time to see how many are formally diagnosed. The goal is to understand gaps in diagnosis and improve care for this common combination of conditions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors identify chronic kidney disease earlier in people with high blood pressure, potentially improving outcomes.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly change patient care. Results may vary by region and practice patterns.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

9,914 people

The number who actually took part.

Started

Apr 2024

Finished

Oct 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

10 000 adult outpatients with AH, who have one or more CKD laboratory markers (without recorded CKD diagnosis prior to enrolment), and have no DM or CHF, who are monitored and treated by cardiologists or internal medicine specialists

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female participants aged 18 years or older at the time of signing the ICF; 2. Signed and dated written informed consent in accordance with ICH GCP and local law prior to inclusion in the study; 3. Diagnosis of AH (essential hypertension) previously established in accordance with current Russian "Clinical guidelines on arterial hypertension in adults", i.e. office systolic blood pressure (SBP) ≥140 mmHg and/or diastolic blood pressure (DBP) ≥90 mmHg, measured on two different visits; 4. Laboratory markers of CKD (eGFR \< 60 ml/min/1,73 m2 and/or albuminuria/proteinuria\*), measured for the period of ≤12 months prior to enrolment. \*any of the following: urine ACR (albumin/creatinine ratio) ≥ 30 mg/g (3 mg/mmol), urine PCR (protein/creatinine ratio) ≥150 mg/g (15 mg/mmol), 24-h albuminuria ≥30 mg/day or 24-h proteinuria ≥ 0.15 g/day. 5. No CKD diagnosis recorded in a patient's medical documents prior to enrollment Exclusion Criteria: 1. The diagnosis of symptomatic chronic heart failure (CHF) II-IV functional class according to the NYHA classification ever recorded in a patient's medical documents; 2. The diagnosis of diabetes mellitus (DM type 1 or DM type 2) recorded in a patient's medical documents; 3. The diagnosis of AH of secondary origin; 4. Participation in any randomized controlled trial within 3 months before the inclusion in this study or during the participation in this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arterial hypertension, chronic kidney disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic renal failure syndrome essential hypertension hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arterial hypertension, chronic kidney disease

Contacts and locations

Locations

  • Research Site

    Aramil, Russia

  • Research Site

    Chelyabinsk, Russia

  • Research Site

    Irkutsk, Russia

  • Research Site

    Kaluga, Russia

  • Research Site

    Kazan', Russia

  • Research Site

    Kemerovo, Russia

  • Research Site

    Krasnodar, Russia

  • Research Site

    Krasnoyarsk, Russia

  • Research Site

    Moscow, Russia

  • Research Site

    Nizhny Novgorod, Russia

  • Research Site

    Novosibirsk, Russia

  • Research Site

    Odintsovo, Russia

  • Research Site

    Omsk, Russia

  • Research Site

    Penza, Russia

  • Research Site

    Perm, Russia

  • Research Site

    Reutov, Russia

  • Research Site

    Rostov-on-Don, Russia

  • Research Site

    Ryazan, Russia

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Samara, Russia

  • Research Site

    Stavropol, Russia

  • Research Site

    Tomsk, Russia

  • Research Site

    Tula, Russia

  • Research Site

    Ufa, Russia

  • Research Site

    Ulan-Ude, Russia

  • Research Site

    Volgograd, Russia

  • Research Site

    Vologda, Russia

  • Research Site

    Voronezh, Russia

  • Research Site

    Yaroslavl, Russia

  • Research Site

    Yekaterinburg, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.